ClinicalTrials.gg
CompletedNCT05963932Updated Jan 23, 2024

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

A Phase 1 interventional study of BMS-986419 DR Capsule and BMS-986419 IR Tablet in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the impact of the BMS-986419 new immediate release (IR) tablet formulation compared to the current enteric (DR) capsule formulation, and to assess the effect of food on the drug levels of the IR tablet formulation in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BMS-986419
  • Healthy male of non-child bearing potential
  • Healthy women of non-child bearing potential
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants without deviation from normal, as determined by the investigator, in medical history, physical examination, vital signs, 12-lead , and clinical laboratory evaluations.
  • (BMI) of 18.0 to 32.0 kilograms per meter squared (kg/m\^2), inclusive, and body weight ≥ 50 kg.
  • A female participant is eligible to participate if she is a woman not of (WNOCBP)

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness (eg, history of intracranial or intraspinal hemorrhage, CNS lesions, recent bacterial or fungal meningitis, etcetera) as determined by the investigator.
  • Current or recent (within 3 months of study intervention administration) gastrointestinal disease that could affect the absorption, distribution, metabolism, and excretion of study intervention (for example, bariatric procedure).
  • History of Gilbert's syndrome.
  • Women who are of and women who are breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Treatment A: BMS-986419 DR Capsule - Fasted

    Drug: BMS-986419 DR Capsule

  • Experimental
    Treatment B: BMS-986419 IR Tablet - Fasted

    Drug: BMS-986419 IR Tablet

  • Experimental
    Treatment C: BMS-986419 IR Tablet - Fed

    Drug: BMS-986419 IR Tablet

  • Experimental
    Treatment D: BMS-986419 Crushed IR Tablet - Fed

    Drug: BMS-986419 IR Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 15 days

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])

    Time frame: Up to 15 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])

    Time frame: Up to 15 days

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 29 days

  2. Number of participants with vital sign abnormalities

    Time frame: Up to 29 days

  3. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 29 days

  4. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 29 days

  5. Number of participants with physical examination abnormalities

    Time frame: Up to 29 days

  6. Time to attain maximum observed plasma concentration (Tmax)

    Time frame: Up to 15 days

  7. Terminal half-life (T-Half)

    Time frame: Up to 15 days

  8. Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24))

    Time frame: Up to 15 days

07

Study locations

1 site
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-andpartners/ clinical-trials-andresearch/disclosure-commitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Oct 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Jul 27, 2023
StartActual
Aug 8, 2023
Primary completionActual
Oct 17, 2023
CompletionActual
Oct 17, 2023
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05963932
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Aug 8, 2023
Primary completion
Oct 17, 2023
Completion
Oct 17, 2023
Last update
Jan 23, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Comtifator

Start the discussion